Sheridan William P

SEC source: 0001127602-22-009124 · form4.xml · derivative · entry 4

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 148,302 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-009124 · form4.xml · nonDerivative · entry 3

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,954

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.53 to $17.79. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-009124 · form4.xml · nonDerivative · entry 2

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,354

F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.53 to $17.52. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-009124 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,093

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-031118 · form4.xml · derivative · entry 2

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031118 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,791

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-018509 · form4.xml · derivative · entry 14

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,901 shares

Expires 2023-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · derivative · entry 13

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 64,299 shares

Expires 2022-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · derivative · entry 12

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,614 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 8

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,475

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 7

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 6

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,388

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 5

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · derivative · entry 11

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,901

Underlying: Common Stock · 11,099 shares

Expires 2023-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · derivative · entry 10

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,299

Underlying: Common Stock · 35,701 shares

Expires 2022-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · derivative · entry 9

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,614

Underlying: Common Stock · 24,959 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 4

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,475

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 3

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 2

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-018509 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,434

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-007642 · form4.xml · derivative · entry 3

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 41,250 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-007642 · form4.xml · nonDerivative · entry 2

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,475

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $11.50 to $11.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-21-007642 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-20-031786 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,000

Underlying: Common Stock · 335,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-030704 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2023-08-08

F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

SEC source: 0001127602-20-007640 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,600

Underlying: Common Stock · 22,600 shares

Expires 2024-12-22

F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested.

SEC source: 0001127602-20-006497 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,550

Underlying: Common Stock · 39,550 shares

Expires 2024-12-22

F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested.

SEC source: 0001127602-19-035547 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,000

Underlying: Common Stock · 176,000 shares

Expires 2029-12-17

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-19-000720 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,638

F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015.

SEC source: 0001127602-18-037170 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,000

Underlying: Common Stock · 335,000 shares

Expires 2028-12-20

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-18-036977 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,725

F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.50 to $7.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-18-025155 · form4.xml · derivative · entry 3

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,500 shares

Expires 2023-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017.

SEC source: 0001127602-18-025155 · form4.xml · nonDerivative · entry 2

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,213

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.00 to $7.16. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-18-025155 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017.

SEC source: 0001127602-18-019981 · form4.xml · derivative · entry 3

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,112 shares

Expires 2018-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-019981 · form4.xml · nonDerivative · entry 2

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,058

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017 and due to the upcoming expiry of the option.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.23 to $6.46. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-18-019981 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2017 and due to the upcoming expiry of the option.

SEC source: 0001127602-18-002233 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,058

F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014.

SEC source: 0001127602-18-000303 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,686

F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015.

SEC source: 0001127602-17-035399 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2027-12-20

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-17-032183 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,855

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person and represents approximately 6 percent of the reporting person's pre-sale vested and unvested holdings.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.65 to $4.78. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-17-026940 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,900

Underlying: Common Stock · 33,900 shares

Expires 2024-12-22

F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017.

SEC source: 0001127602-17-009095 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2027-02-27

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-17-002248 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,916

F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014.

SEC source: 0001127602-17-000069 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,677

F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015.